In cancer therapy, enhanced synthetic phagocytic receptors integrate FcRγ chain-driven CAR structures with secreted CD47 blockers, allowing macrophages to bypass tumor antigen heterogeneity. This evidence concerns the gene CD47 and neoplasm.